



MCO Amendment 9
Attachment H9 – Changes to Attachment H, Quality Performance Measures

Note: All measures are renumbered based on changes made.

Item	Change From		Change To		Justification								
1.	[new measure]		<table border="1"> <thead> <tr> <th data-bbox="1155 451 1532 488">Measures</th> <th data-bbox="1532 451 2042 488">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 488 1532 677"> <u>3. Antibiotic Utilization for Respiratory Conditions (AXR)</u> </td> <td data-bbox="1532 488 2042 677"> <u>The percentage of episodes for members three (3) months of age and older with a diagnosis of a respiratory condition that resulted in an antibiotic dispensing event.</u> </td> </tr> </tbody> </table>	Measures	Measure Description	<u>3. Antibiotic Utilization for Respiratory Conditions (AXR)</u>	<u>The percentage of episodes for members three (3) months of age and older with a diagnosis of a respiratory condition that resulted in an antibiotic dispensing event.</u>		This revision is an NCQA requirement.				
Measures	Measure Description												
<u>3. Antibiotic Utilization for Respiratory Conditions (AXR)</u>	<u>The percentage of episodes for members three (3) months of age and older with a diagnosis of a respiratory condition that resulted in an antibiotic dispensing event.</u>												
2.	<table border="1"> <thead> <tr> <th data-bbox="236 690 610 727">Measures</th> <th data-bbox="610 690 1123 727">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="236 727 610 1010">3. Inpatient Utilization -- General Hospital/Acute Care (IPU)</td> <td data-bbox="610 727 1123 1010"> This measure summarizes utilization of acute inpatient care and services in the following categories: <ul style="list-style-type: none"> • Maternity • Surgery • Medicine • Total inpatient (the sum of Maternity, Surgery and Medicine) </td> </tr> </tbody> </table>	Measures	Measure Description	3. Inpatient Utilization -- General Hospital/Acute Care (IPU)	This measure summarizes utilization of acute inpatient care and services in the following categories: <ul style="list-style-type: none"> • Maternity • Surgery • Medicine • Total inpatient (the sum of Maternity, Surgery and Medicine) 		<table border="1"> <thead> <tr> <th data-bbox="1155 690 1532 727">Measures</th> <th data-bbox="1532 690 2042 727">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 727 1532 1010"> 3. Inpatient Utilization General Hospital/Acute Care (IPU) </td> <td data-bbox="1532 727 2042 1010"> This measure summarizes utilization of acute inpatient care and services in the following categories: <ul style="list-style-type: none"> • Maternity • Surgery • Medicine • Total inpatient (the sum of Maternity, Surgery and Medicine) </td> </tr> </tbody> </table>	Measures	Measure Description	3. Inpatient Utilization General Hospital/Acute Care (IPU)	This measure summarizes utilization of acute inpatient care and services in the following categories: <ul style="list-style-type: none"> • Maternity • Surgery • Medicine • Total inpatient (the sum of Maternity, Surgery and Medicine) 		NCQA retired this measure.
Measures	Measure Description												
3. Inpatient Utilization -- General Hospital/Acute Care (IPU)	This measure summarizes utilization of acute inpatient care and services in the following categories: <ul style="list-style-type: none"> • Maternity • Surgery • Medicine • Total inpatient (the sum of Maternity, Surgery and Medicine) 												
Measures	Measure Description												
3. Inpatient Utilization General Hospital/Acute Care (IPU)	This measure summarizes utilization of acute inpatient care and services in the following categories: <ul style="list-style-type: none"> • Maternity • Surgery • Medicine • Total inpatient (the sum of Maternity, Surgery and Medicine) 												
3.	<table border="1"> <thead> <tr> <th data-bbox="236 1023 610 1060">Measures</th> <th data-bbox="610 1023 1123 1060">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="236 1060 610 1334">5. Ambulatory Care</td> <td data-bbox="610 1060 1123 1334"> This measure summarizes utilization of ambulatory care in the following categories: <ul style="list-style-type: none"> • Outpatient Visits Including Telehealth. • ED Visits <i>Note: A lower rate indicates better performance for ED visits.</i> </td> </tr> </tbody> </table>	Measures	Measure Description	5. Ambulatory Care	This measure summarizes utilization of ambulatory care in the following categories: <ul style="list-style-type: none"> • Outpatient Visits Including Telehealth. • ED Visits <i>Note: A lower rate indicates better performance for ED visits.</i>		<table border="1"> <thead> <tr> <th data-bbox="1155 1023 1532 1060">Measures</th> <th data-bbox="1532 1023 2042 1060">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 1060 1532 1334"> 5. Ambulatory Care </td> <td data-bbox="1532 1060 2042 1334"> This measure summarizes utilization of ambulatory care in the following categories: <ul style="list-style-type: none"> • Outpatient Visits Including Telehealth. • ED Visits <i>Note: A lower rate indicates better performance for ED visits.</i> </td> </tr> </tbody> </table>	Measures	Measure Description	5. Ambulatory Care	This measure summarizes utilization of ambulatory care in the following categories: <ul style="list-style-type: none"> • Outpatient Visits Including Telehealth. • ED Visits <i>Note: A lower rate indicates better performance for ED visits.</i>		NCQA retired this measure.
Measures	Measure Description												
5. Ambulatory Care	This measure summarizes utilization of ambulatory care in the following categories: <ul style="list-style-type: none"> • Outpatient Visits Including Telehealth. • ED Visits <i>Note: A lower rate indicates better performance for ED visits.</i>												
Measures	Measure Description												
5. Ambulatory Care	This measure summarizes utilization of ambulatory care in the following categories: <ul style="list-style-type: none"> • Outpatient Visits Including Telehealth. • ED Visits <i>Note: A lower rate indicates better performance for ED visits.</i>												

Item	Change From	Change To		Justification				
4.	[new measure]	<table border="1"> <thead> <tr> <th data-bbox="1155 269 1532 310">Measures</th> <th data-bbox="1532 269 2040 310">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 310 1532 951"> <u>8. Follow-Up After High Intensity Care for Substance Use Disorder (FUI)</u> </td> <td data-bbox="1532 310 2040 951"> <u>The percentage of acute inpatient hospitalizations, residential treatment or withdrawal management visits for a diagnosis of substance use disorder among members thirteen (13) years of age and older that result in a follow-up visit or service for substance use disorder. Two (2) rates are reported:</u> <u>1. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the thirty (30) days after the visit or discharge.</u> <u>2. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the seven (7) days after the visit or discharge.</u> </td> </tr> </tbody> </table>	Measures	Measure Description	<u>8. Follow-Up After High Intensity Care for Substance Use Disorder (FUI)</u>	<u>The percentage of acute inpatient hospitalizations, residential treatment or withdrawal management visits for a diagnosis of substance use disorder among members thirteen (13) years of age and older that result in a follow-up visit or service for substance use disorder. Two (2) rates are reported:</u> <u>1. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the thirty (30) days after the visit or discharge.</u> <u>2. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the seven (7) days after the visit or discharge.</u>		This revision is an NCQA requirement.
Measures	Measure Description							
<u>8. Follow-Up After High Intensity Care for Substance Use Disorder (FUI)</u>	<u>The percentage of acute inpatient hospitalizations, residential treatment or withdrawal management visits for a diagnosis of substance use disorder among members thirteen (13) years of age and older that result in a follow-up visit or service for substance use disorder. Two (2) rates are reported:</u> <u>1. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the thirty (30) days after the visit or discharge.</u> <u>2. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the seven (7) days after the visit or discharge.</u>							
5.	21. Cesarean Rate for Low-Risk First Birth Women	21. <u>Low-Risk Cesarean Delivery Rate for Low-Risk First Birth Women</u>		This revision is an update from NCQA.				

Item	Change From		Change To		Justification								
6.	[new measure]		<table border="1"> <thead> <tr> <th data-bbox="1145 269 1542 310">Measures</th> <th data-bbox="1542 269 2040 310">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1145 310 1542 565"><u>28. Appropriate Testing for Pharyngitis (CWP)</u></td> <td data-bbox="1542 310 2040 565"><u>The percentage of episodes for members three (3) years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode</u></td> </tr> </tbody> </table>	Measures	Measure Description	<u>28. Appropriate Testing for Pharyngitis (CWP)</u>	<u>The percentage of episodes for members three (3) years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode</u>		This revision is an NCQA requirement.				
Measures	Measure Description												
<u>28. Appropriate Testing for Pharyngitis (CWP)</u>	<u>The percentage of episodes for members three (3) years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode</u>												
7.	<table border="1"> <thead> <tr> <th data-bbox="223 565 620 605">Measures</th> <th data-bbox="620 565 1120 605">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="223 605 620 1008">27. Oral evaluation, Dental Services (OED)</td> <td data-bbox="620 605 1120 1008"> The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year. Report four age stratifications and a total rate: <ul style="list-style-type: none"> • 0-2 years • 3-5 years • 6-14 years • 15-20 years • Total </td> </tr> </tbody> </table>	Measures	Measure Description	27. Oral evaluation, Dental Services (OED)	The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year. Report four age stratifications and a total rate: <ul style="list-style-type: none"> • 0-2 years • 3-5 years • 6-14 years • 15-20 years • Total 		<table border="1"> <thead> <tr> <th data-bbox="1145 565 1542 605">Measures</th> <th data-bbox="1542 565 2040 605">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1145 605 1542 1008">27. Oral evaluation, Dental Services (OED)</td> <td data-bbox="1542 605 2040 1008"> The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year. Report four age stratifications and a total rate: <ul style="list-style-type: none"> • 0-2 years • 3-5 years • 6-14 years • 15-20 years • Total </td> </tr> </tbody> </table>	Measures	Measure Description	27. Oral evaluation, Dental Services (OED)	The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year. Report four age stratifications and a total rate: <ul style="list-style-type: none"> • 0-2 years • 3-5 years • 6-14 years • 15-20 years • Total 		NCQA retired this measure.
Measures	Measure Description												
27. Oral evaluation, Dental Services (OED)	The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year. Report four age stratifications and a total rate: <ul style="list-style-type: none"> • 0-2 years • 3-5 years • 6-14 years • 15-20 years • Total 												
Measures	Measure Description												
27. Oral evaluation, Dental Services (OED)	The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year. Report four age stratifications and a total rate: <ul style="list-style-type: none"> • 0-2 years • 3-5 years • 6-14 years • 15-20 years • Total 												
8.	<table border="1"> <thead> <tr> <th data-bbox="223 1008 620 1049">Measures</th> <th data-bbox="620 1008 1120 1049">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="223 1049 620 1372"></td> <td data-bbox="620 1049 1120 1372"></td> </tr> </tbody> </table>	Measures	Measure Description				<table border="1"> <thead> <tr> <th data-bbox="1145 1008 1542 1049">Measures</th> <th data-bbox="1542 1008 2040 1049">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1145 1049 1542 1372">30. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents – Body Mass Index Assessment for Children/Adolescents <u>(WCC)</u></td> <td data-bbox="1542 1049 2040 1372"> The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year. <ul style="list-style-type: none"> • BMI percentile documentation • Counseling for nutrition • Counseling for physical activity </td> </tr> </tbody> </table>	Measures	Measure Description	30. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents – Body Mass Index Assessment for Children/Adolescents <u>(WCC)</u>	The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year. <ul style="list-style-type: none"> • BMI percentile documentation • Counseling for nutrition • Counseling for physical activity 		This revision is an NCQA requirement.
Measures	Measure Description												
Measures	Measure Description												
30. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents – Body Mass Index Assessment for Children/Adolescents <u>(WCC)</u>	The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year. <ul style="list-style-type: none"> • BMI percentile documentation • Counseling for nutrition • Counseling for physical activity 												

Item	Change From		Change To		Justification								
	30. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents – Body Mass Index Assessment for Children/Adolescents	The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year. <ul style="list-style-type: none"> BMI percentile documentation Counseling for nutrition Counseling for physical activity 		<u>*Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.</u>									
9.	<table border="1"> <thead> <tr> <th data-bbox="225 889 620 928">Measures</th> <th data-bbox="620 889 1145 928">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="225 928 620 1253">36. Cervical Cancer Screening</td> <td data-bbox="620 928 1145 1253"> \$\$: Percentage of women 21–64 years of age who were screened for cervical cancer: <ul style="list-style-type: none"> Women 21-64 who had cervical cytology performed every 3 years. Women 30-64 who had cervical cytology/HPV co-testing performed every 5 years. </td> </tr> </tbody> </table>	Measures	Measure Description	36. Cervical Cancer Screening	\$\$: Percentage of women 21–64 years of age who were screened for cervical cancer: <ul style="list-style-type: none"> Women 21-64 who had cervical cytology performed every 3 years. Women 30-64 who had cervical cytology/HPV co-testing performed every 5 years. 		<table border="1"> <thead> <tr> <th data-bbox="1145 889 1540 928">Measures</th> <th data-bbox="1540 889 2134 928">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1145 928 1540 1359">36. Cervical Cancer Screening (CCS)</td> <td data-bbox="1540 928 2134 1359"> \$\$: Percentage of women 21–64 years of age who were screened for cervical cancer: <ul style="list-style-type: none"> Women 21-64 who had cervical cytology performed every 3 years. Women 30-64 who had cervical cytology/HPV co-testing performed every 5 years. <u>The percentage of women 21–64 years of age who were recommended for routine cervical cancer screening who</u> </td> </tr> </tbody> </table>	Measures	Measure Description	36. Cervical Cancer Screening (CCS)	\$\$: Percentage of women 21–64 years of age who were screened for cervical cancer: <ul style="list-style-type: none"> Women 21-64 who had cervical cytology performed every 3 years. Women 30-64 who had cervical cytology/HPV co-testing performed every 5 years. <u>The percentage of women 21–64 years of age who were recommended for routine cervical cancer screening who</u>		This revision is an NCQA requirement.
Measures	Measure Description												
36. Cervical Cancer Screening	\$\$: Percentage of women 21–64 years of age who were screened for cervical cancer: <ul style="list-style-type: none"> Women 21-64 who had cervical cytology performed every 3 years. Women 30-64 who had cervical cytology/HPV co-testing performed every 5 years. 												
Measures	Measure Description												
36. Cervical Cancer Screening (CCS)	\$\$: Percentage of women 21–64 years of age who were screened for cervical cancer: <ul style="list-style-type: none"> Women 21-64 who had cervical cytology performed every 3 years. Women 30-64 who had cervical cytology/HPV co-testing performed every 5 years. <u>The percentage of women 21–64 years of age who were recommended for routine cervical cancer screening who</u>												

Item	Change From		Change To		Justification							
			<p><u>were screened for cervical cancer using any of the following criteria:</u></p> <ul style="list-style-type: none"> <u>• Members 21–64 years of age who were recommended for routine cervical cancer screening and had cervical cytology performed within the last three (3) years.</u> <u>• Members 30–64 years of age who were recommended for routine cervical cancer screening and had cervical high-risk human papillomavirus (hrHPV) testing performed within the last five (5) years.</u> <u>• Members 30–64 years of age who were recommended for routine cervical cancer screening and had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the last five (5) years.</u> 									
10.	<table border="1"> <thead> <tr> <th data-bbox="225 951 620 992">Measures</th> <th data-bbox="620 951 1145 992">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="225 992 620 1356">44. Hemoglobin A1c Control for Patients With Diabetes</td> <td data-bbox="620 992 1145 1356"> <p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> HbA1c control (<8.0%). \$\$ HbA1c poor control (>9.0%) <p><i>Note: A lower rate indicates better performance for HbA1c poor control (i.e.,</i></p> </td> </tr> </tbody> </table>	Measures	Measure Description	44. Hemoglobin A1c Control for Patients With Diabetes	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> HbA1c control (<8.0%). \$\$ HbA1c poor control (>9.0%) <p><i>Note: A lower rate indicates better performance for HbA1c poor control (i.e.,</i></p>		<table border="1"> <thead> <tr> <th data-bbox="1145 951 1540 992">Measures</th> <th data-bbox="1540 951 2134 992">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1145 992 1540 1356">44. Hemoglobin A1c Control for Patients With Diabetes <u>44. Glycemic Status Assessment for Patients With Diabetes (GSD)</u></td> <td data-bbox="1540 992 2134 1356"> <p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> • HbA1c control (<8.0%). • \$\$ HbA1c poor control (>9.0%) <p><i>Note: A lower rate indicates better performance for HbA1c poor control (i.e.,</i></p> </td> </tr> </tbody> </table>	Measures	Measure Description	44. Hemoglobin A1c Control for Patients With Diabetes <u>44. Glycemic Status Assessment for Patients With Diabetes (GSD)</u>	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> • HbA1c control (<8.0%). • \$\$ HbA1c poor control (>9.0%) <p><i>Note: A lower rate indicates better performance for HbA1c poor control (i.e.,</i></p>	This revision is an NCQA requirement.
Measures	Measure Description											
44. Hemoglobin A1c Control for Patients With Diabetes	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> HbA1c control (<8.0%). \$\$ HbA1c poor control (>9.0%) <p><i>Note: A lower rate indicates better performance for HbA1c poor control (i.e.,</i></p>											
Measures	Measure Description											
44. Hemoglobin A1c Control for Patients With Diabetes <u>44. Glycemic Status Assessment for Patients With Diabetes (GSD)</u>	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> • HbA1c control (<8.0%). • \$\$ HbA1c poor control (>9.0%) <p><i>Note: A lower rate indicates better performance for HbA1c poor control (i.e.,</i></p>											

Item	Change From		Change To		Justification								
	<p><i>low rates of poor control indicate better care).</i></p>		<p><i>low rates of poor control indicate better care).</i></p> <p><u>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement year:</u></p> <ul style="list-style-type: none"> • <u>Glycemic Status <8.0%.</u> • <u>Glycemic Status >9.0%.</u> <p><u>Note: Organizations must use the same data collection method (Administrative or Hybrid) to report these indicators</u></p>										
11.	<table border="1"> <thead> <tr> <th data-bbox="236 808 620 846">Measures</th> <th data-bbox="620 808 1134 846">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="236 846 620 1099">64. Non-recommended Cervical Cancer Screening in Adolescent Females</td> <td data-bbox="620 846 1134 1099">The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. <i>Note: A lower rate indicates better performance.</i></td> </tr> </tbody> </table>		Measures	Measure Description	64. Non-recommended Cervical Cancer Screening in Adolescent Females	The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. <i>Note: A lower rate indicates better performance.</i>	<table border="1"> <thead> <tr> <th data-bbox="1155 808 1540 846">Measures</th> <th data-bbox="1540 808 2123 846">Measure Description</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 846 1540 1099">64. Non-recommended Cervical Cancer Screening in Adolescent Females</td> <td data-bbox="1540 846 2123 1099">The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. <i>Note: A lower rate indicates better performance.</i></td> </tr> </tbody> </table>		Measures	Measure Description	64. Non-recommended Cervical Cancer Screening in Adolescent Females	The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. <i>Note: A lower rate indicates better performance.</i>	NCQA retired this measure.
Measures	Measure Description												
64. Non-recommended Cervical Cancer Screening in Adolescent Females	The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. <i>Note: A lower rate indicates better performance.</i>												
Measures	Measure Description												
64. Non-recommended Cervical Cancer Screening in Adolescent Females	The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. <i>Note: A lower rate indicates better performance.</i>												
12.	[abbreviation added to certain measures]		<table border="1"> <thead> <tr> <th data-bbox="1155 1105 2123 1143">Measures</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 1143 2123 1180">1. Child and Adolescent Well-Care Visits (<u>WCV</u>)</td> </tr> <tr> <td data-bbox="1155 1180 2123 1218">2. Well-Child Visits in the First 30 Months of Life (<u>W30</u>)</td> </tr> <tr> <td data-bbox="1155 1218 2123 1255">3. <u>Antibiotic Utilization for Respiratory Conditions (AXR)</u></td> </tr> <tr> <td data-bbox="1155 1255 2123 1292">4. Adult Access to Preventive/Ambulatory Services (<u>AAP</u>)</td> </tr> <tr> <td data-bbox="1155 1292 2123 1330">5. Follow-Up After Hospitalization for Mental Illness (<u>FUH</u>)</td> </tr> <tr> <td data-bbox="1155 1330 2123 1399">6. Follow-Up After Emergency Department Visit for Mental Illness (<u>FUM</u>)</td> </tr> </tbody> </table>		Measures	1. Child and Adolescent Well-Care Visits (<u>WCV</u>)	2. Well-Child Visits in the First 30 Months of Life (<u>W30</u>)	3. <u>Antibiotic Utilization for Respiratory Conditions (AXR)</u>	4. Adult Access to Preventive/Ambulatory Services (<u>AAP</u>)	5. Follow-Up After Hospitalization for Mental Illness (<u>FUH</u>)	6. Follow-Up After Emergency Department Visit for Mental Illness (<u>FUM</u>)	These revisions provide abbreviations to most measures for ease of reference.	
Measures													
1. Child and Adolescent Well-Care Visits (<u>WCV</u>)													
2. Well-Child Visits in the First 30 Months of Life (<u>W30</u>)													
3. <u>Antibiotic Utilization for Respiratory Conditions (AXR)</u>													
4. Adult Access to Preventive/Ambulatory Services (<u>AAP</u>)													
5. Follow-Up After Hospitalization for Mental Illness (<u>FUH</u>)													
6. Follow-Up After Emergency Department Visit for Mental Illness (<u>FUM</u>)													

Item	Change From	Change To	Justification
		<p>7. Follow-Up After Emergency Department Visit for Substance Use (FUA)</p> <p>8. Follow-Up After High Intensity Care for Substance Use Disorder (FUI)</p> <p>9. Plan All-Cause Readmissions (PCR)</p> <p>10. Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Health Plan Survey 5.1H – Child Version (Medicaid) (CPC)</p> <p>11. Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Health Plan Survey 5.1H, Adult Version (Medicaid) (CPA)</p> <p>12. Children with Chronic Conditions (CCC)</p> <p>13. Depression Screening and Follow-Up for Adolescents and Adults (DSF)</p> <p>14. Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</p> <p>15. Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD)</p> <p>16. Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)</p> <p>17. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)</p> <p>18. Self-Reported Overall Health (Adult and Child)</p> <p>19. Self-Reported Overall Mental or Emotional Health (Adult and Child)</p> <p>20. Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC)</p> <p>21. Low-Risk Cesarean Delivery</p> <p>22. Prenatal and Postpartum Care: Postpartum Care (PPC)</p> <p>23. Percentage of Low Birthweight Births</p> <p>24. Developmental Screening in the First Three Years of Life</p> <p>25. Lead Screening in Children (LSC)</p> <p>26. Topical Fluoride for Children (TFC)</p> <p>27. Appropriate Testing for Pharyngitis (CWP)</p> <p>28. Childhood Immunization Status (CIS)</p> <p>29. Immunizations for Adolescents (IMA)</p>	

Item	Change From	Change To	Justification
		30. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents – Body Mass Index Assessment for Children/Adolescents (WCC)	
		31. Contraceptive Care – All Women Ages 15 - 20	
		32. Contraceptive Care – Postpartum Women Ages 15-20	
		33. Contraceptive Care – All Women Ages 21–44	
		34. Contraceptive Care – Postpartum Women Ages 21–44	
		35. Chlamydia Screening in Women (CHL)	
		36. Cervical Cancer Screening (CCS)	
		37. Colorectal Cancer Screening (COL)	
		38. Hepatitis C Virus Screening	
		39. Medical Assistance With Smoking and Tobacco Use Cessation (MSC)	
		40. Controlling High Blood Pressure (CBP)	
		41. Diabetes Short-Term Complications Admission Rate	
		42. Statin Therapy for Patients with Cardiovascular Disease (SPC)	
		43. Heart Failure Admission Rate	
		44. Glycemic Status Assessment for Patients With Diabetes (GSD)	
		45. Blood Pressure Control for Patients With Diabetes (BPD)	
		46. Eye Exam for Patients With Diabetes (EED)	
		47. Asthma in Younger Adults Admission Rate	
		48. Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate	
		49. Asthma Medication Ratio	
		50. HIV Viral Load Suppression	
		51. Pharmacotherapy for Opioid Use Disorder (POD)	
		52. Initiation and Engagement of Substance Use Disorder Treatment (IET)	
		53. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	
		54. Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)	

Item	Change From	Change To	Justification				
		55. Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder Medication <u>(ADD)</u> 56. Antidepressant Medication Management <u>(AMM)</u> 57. Measures for stratified data: 58. Enrollment by Product Line <u>(ENP)</u> 59. Language Diversity of Membership <u>(LDM)</u> 60. Race/Ethnicity Diversity of Membership <u>(RDM)</u> 61. Appropriate Treatment for Children With Upper Respiratory Infection <u>(URI)</u> 62. Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis <u>(AAB)</u> 63. Use of Imaging Studies for Low Back Pain <u>(LBP)</u>					
13.	[correction of steward]	<table border="1"> <thead> <tr> <th data-bbox="1155 716 1542 748">Measures</th> <th data-bbox="1542 716 2040 748">Steward</th> </tr> </thead> <tbody> <tr> <td data-bbox="1155 748 1542 859">13. Depression Screening and Follow-Up for Adolescents and Adults (DSF)</td> <td data-bbox="1542 748 2040 859">NCQA-CMS</td> </tr> </tbody> </table>	Measures	Steward	13. Depression Screening and Follow-Up for Adolescents and Adults (DSF)	NCQA-CMS	This revision corrects an error.
Measures	Steward						
13. Depression Screening and Follow-Up for Adolescents and Adults (DSF)	NCQA-CMS						